Multiple sclerosis / − nikotyna

Nicotinic attenuation of CNS inflammation and autoimmunity

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

BACKGROUND All publications herein are incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. The following description includes information that may be useful in understanding

Nicotinic attenuation of CNS inflammation and autoimmunity

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

BACKGROUND All publications herein are incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. The following description includes information that may be useful in understanding

Nicotinic attenuation of CNS inflammation and autoimmunity

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

BACKGROUND All publications herein are incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. The following description includes information that may be useful in understanding

Thieno-pyridine derivatives as allosteric enhancers of the GABA.sub.B receptors

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

PRIORITY TO RELATED APPLICATIONS This application claims the benefit of European Application No. 04106665.5, filed Dec. 17, 2004, which is hereby incorporated by reference in its entirety. BACKGROUND OF THE INVENTION .gamma.-Aminobutyric acid (GABA), the most abundant inhibitory neurotransmitter,

Urea compounds and their use as enzyme inhibitors

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

FIELD OF THE INVENTION The present invention relates to compounds and their uses, and in particular to compounds and their therapeutic use in the treatment or prevention of conditions having an association with substrates, such as the neurotransmitter anandamide, which are broken down by the fatty

Urea compounds and their use as enzyme inhibitors

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

FIELD OF THE INVENTION The present invention relates to compounds and their uses, and in particular to compounds and their therapeutic use in the treatment or prevention of conditions having an association with substrates, such as the neurotransmitter anandamide, which are broken down by the fatty

Triazinedione derivatives as GABA.sub.B receptor modulators

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

SUMMARY OF THE INVENTION ##STR00002## The present invention provides novel compounds of formula I wherein W.sub.1, W.sub.2, W.sub.3, W.sub.4, W.sub.5, B, X.sub.1, X.sub.2, X.sub.3, X.sub.4, X.sub.5, E and L are as defined herein; invention compounds are gamma amino butyric acid receptor-subtype B

Triazinedione derivatives as GABA.sub.B receptor modulators

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

SUMMARY OF THE INVENTION ##STR00002## The present invention provides novel compounds of formula I wherein W.sub.1, W.sub.2, W.sub.3, W.sub.4, W.sub.5, B, X.sub.1, X.sub.2, X.sub.3, X.sub.4, X.sub.5, E and L are as defined herein; invention compounds are gamma amino butyric acid receptor-subtype B

Aromatic and heteroaromatic substituted amides

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

FIELD OF INVENTION The invention relates to a compound of formula ##STR1## wherein R.sup.1 is selected from the group consisting of hydrogen and fluoro. Compounds of formula 1, and pharmaceutically acceptable acid addition salts thereof, have been shown to mediate the Neurokinin 1 (NK-1, substance

Aminomethylpyrimidines as allosteric enhancers of the GABA.sub.B receptors

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

FIELD OF THE INVENTION The invention relates to enhancement of GABA.sub.B receptors. The invention further relates to the treatment of CNS disorders, such as anxiety, depression, epilepsy, schizophrenia, cognitive disorders, spasticity and skeletal muscle rigidity, spinal cord injury, multiple

Methods for treating vascular dementia

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

FIELD OF THE INVENTION The invention describes novel methods for treating and preventing dementia caused by vascular diseases; dementia associated with Parkinson's disease; Lewy Body dementia; AIDS dementia; mild cognitive impairments; age-associated memory impairments; cognitive impairments and/or

Methods for treating dementia due to HIV disease

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

FIELD OF THE INVENTION The invention describes novel methods for treating and preventing dementia caused by vascular diseases; dementia associated with Parkinson's disease; Lewy Body dementia; AIDS dementia; mild cognitive impairments; age-associated memory impairments; cognitive impairments and/or

Methods for treating cognitive impairments or dementia

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

FIELD OF THE INVENTION The invention describes novel methods for treating and preventing dementia caused by vascular diseases; dementia associated with Parkinson's disease; Lewy Body dementia; AIDS dementia; mild cognitive impairments; age-associated memory impairments; cognitive impairments and/or

CB1 antagonist compounds

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

BACKGROUND OF THE INVENTION Marijuana (Cannabis sativa L.) and its derivatives have been used for centuries for medicinal and recreational purposes. A major active ingredient in marijuana and hashish has been determined to be .DELTA..sup.9-tetrahydrocannabinol (.DELTA..sup.9-THC). Detailed research

Aralkyl amines as cannabinoid receptor modulators

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

BACKGROUND OF THE INVENTION Marijuana (Cannabis sativa L.) and its derivatives have been used for centuries for medicinal and recreational purposes. A major active ingredient in marijuana and hashish has been determined to be .DELTA.9-tetrahydrocannabinol (.DELTA.9-THC). Detailed research has

multiple sclerosis/− nikotyna

Nicotinic attenuation of CNS inflammation and autoimmunity

Nicotinic attenuation of CNS inflammation and autoimmunity

Nicotinic attenuation of CNS inflammation and autoimmunity

Thieno-pyridine derivatives as allosteric enhancers of the GABA.sub.B receptors

Urea compounds and their use as enzyme inhibitors

Urea compounds and their use as enzyme inhibitors

Triazinedione derivatives as GABA.sub.B receptor modulators

Triazinedione derivatives as GABA.sub.B receptor modulators

Aromatic and heteroaromatic substituted amides

Aminomethylpyrimidines as allosteric enhancers of the GABA.sub.B receptors

Methods for treating vascular dementia

Methods for treating dementia due to HIV disease

Methods for treating cognitive impairments or dementia

CB1 antagonist compounds

Aralkyl amines as cannabinoid receptor modulators

Najbardziej kompletna baza danych ziół leczniczych poparta naukowo